Pfizer Inc. announced the appointment of Adele Gulfo, US president, Primary Care. In this new position, Gulfo is responsible for the company’s US Primary Care business, including its five Regional Business Units, commercial operations, marketing, and corporate and government customer relationships. She reports to Olivier Brandicourt, president and general manager of Pfizer’s Worldwide Primary Care business.
“This is a pivotal moment in health care for our patients and our business, and Adele Gulfo’s scientific and commercial background and diversity of leadership experience in strategy, sales and marketing make her the ideal person to lead the US Primary Care organization,” said Brandicourt.
Gulfo joins Pfizer from AstraZeneca, where she was most recently vice president, business development and design for launch, responsible for sourcing, evaluating and securing external assets including partnerships, acquisitions, and licenses, as well as clinical and commercial development across all therapeutic areas of products entering phase 2b.
She previously led AstraZeneca’s cardiovascular business and played a crucial role in the success of Crestor. She led commercial and development functions, including marketing, sales, clinical development, regulatory and life-cycle management for Crestor and other cardiovascular brands, including Toprol XL, Zestril, Sular, Plendil, and Atacand.